Latest Breaking News On - Technology enterprise consortium under award no - Page 1 : comparemela.com

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury

CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translati.

David dewahlDavida dewahl jrIschemix incAltasciences company incHealth affairsUs army medical researchDepartment of defense contact informationTechnology enterprise consortium under award noDepartment of defenseDevelopment commandCasualty care research programNeurotrauma at combat casualty care research programTechnology enterprise consortiumTechnology internationalPrincipal investigatorChief medical officer

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound .

David dewahlDavida dewahl jrHealth affairsUs army medical researchNeurotrauma at combat casualty care research programIschemix incDevelopment commandTechnology enterprise consortiumCasualty care research programTechnology internationalNews networkTechnology enterprise consortium under award noAltasciences company incDepartment of defensePrincipal investigatorChief medical officer

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial
torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.

David dewahlDavida dewahl jrAltasciences company incHealth affairsIschemix incTechnology enterprise consortiumUs army medical researchTechnology internationalTechnology enterprise consortium under award noNeurotrauma at combat casualty care research programDevelopment commandDepartment of defenseCasualty care research programPrincipal investigatorChief medical officerMedical research

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury ; Preparing for Conduct of Phase 2 Trial

Ischemix, Inc Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury ; Preparing for Conduct of Phase 2 Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Davida dewahl jrDavid dewahlTechnology enterprise consortium under award noNeurotrauma at combat casualty care research programUs army medical researchTechnology internationalIschemix incDevelopment commandHealth affairsDepartment of defenseAltasciences company incTechnology enterprise consortiumCasualty care research programPrincipal investigatorChief medical officerMedical research